Evidence is growing that some HIV-infected infants, if given antiretroviral drugs early in life, are able to suppress their ...

Previous research has shown that HIV-specific CD8 T-cell responses directed against five genetically conserved HIV-1 protein ...

HIV antivirals may be the key to stopping HTLV-1, a deadly virus with no cure. In a decade-long study, researchers ...

With Black women and straight men increasingly at risk, Gilead’s Yeztugo may finally offer a discreet, stigma-free way to ...

Results from early-stage trial show that 80% of participants who received one of two HIV vaccine candidates produced antibodies against viral proteins.

Scientists used a mRNA-based vaccine to reliably trigger antibodies that block HIV infection in people and monkeys ...

In 2024, studies suggested that lenacapavir, already used to treat people with HIV, was nearly 100% effective in stopping ...

In a recent landmark study, scientists have unveiled how HIV-1 penetrates the cell's nuclear barrier—a discovery that could reshape antiviral strategies. The research, led by Professor Peijun Zhang, ...

Receiving treatment within the first month of life could protect children for at least three years, a study suggests.

To find out what may be behind these numbers, Dr. Ann Khalsa, a clinician at the Valleywise Health McDowell Clinic spoke with ...

Declining investment in global health surveillance, research, and scientific innovation are happening as the need for vigilance has never been greater, writes Robert C. Gallo.

Explore the HIV market with our comprehensive report, analyzing disease overview, epidemiology, and current treatments. Discover unmet needs, R&D strategies, and market trends from 2023-2033 in ...